Our Ebola Vaccine Programme
On 6 January 2015 the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine was announced. It will evaluate the safety and tolerability of a prime-boost vaccine regimen. Different regimens combining the vaccine components or placebo will be studied in 72 healthy adult volunteers. Additional clinical studies are planned to begin in the United States later this month and soon after in Africa. Full details of the study are posted on clinicaltrials.gov. The first volunteers have received their initial vaccine dose.
It was also announced that more than 400,000 regimens of the prime-boost vaccine were produced that will become available for use in large-scale clinical trials by April 2015. A total of 2 million doses will be available through the course of 2015, with the ability to quickly scale up to 5 million doses, if required, over a 12- to 18-month period. This increased projection is an update to Janssen’s previous goal of producing more than 1 million doses by the end of 2015, with 250,000 doses for broad application in clinical trials by May 2015.
Read the full press release here.
On 9 October 2015 we announced the start of a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen. Trial recruitment was ongoing and the first volunteers received their initial vaccine dose. This was the first study conducted of Janssen’s Ebola prime-boost vaccine regimen in a West African country affected by the recent Ebola epidemic.